Verona Pharma Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
Portfolio Pulse from
Verona Pharma reported its Q4 and full-year 2024 financial results, highlighting net product sales of $36.6 million for Ohtuvayre TM (ensifentrine) in Q4 and $42.3 million for the year.
February 27, 2025 | 11:15 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Verona Pharma's financial results for Q4 and 2024 show strong sales for Ohtuvayre TM (ensifentrine), with $36.6 million in Q4 and $42.3 million for the year.
The reported sales figures for Ohtuvayre TM (ensifentrine) indicate strong performance, which is likely to positively impact Verona Pharma's stock price in the short term. The financial results suggest growth and successful product performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100